Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Canvas Pharmaceuticals Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions. This count represents the total number of active procedural matters the company is currently addressing.
The prosecution is distributed across 3 distinct examiners and 3 distinct art units. The number of pending office actions matches the number of examiners and art units, which suggests that the company's intellectual property is spread across several different technical specialties. Each of the 3 pending office actions is being reviewed in a unique administrative environment.
OSWALD, KIRSTIN U is identified as the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner handles 1 of the 3 total pending actions. This distribution means that the company must manage three separate examiner relationships and navigate the specific requirements of 3 distinct art units simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OSWALD, KIRSTIN U | 1 | 59.4% | +32.1% |
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18120514 | LARGE SCALE SYNTHESIS OF PHARMACEUTICAL AND BIOLOGIC FORMULATIONS USING THIN FILM FREEZING | OSWALD, KIRSTIN U | — |
| 18082963 | COMPOSITIONS COMPRISING VORICONAZOLE INHALATION POWDER AND METHODS OF MANUFACTURE AND USE THEREOF | RAO, SAVITHA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18120514 | LARGE SCALE SYNTHESIS OF PHARMACEUTICAL AND BIOLOGIC FORMULATIONS USING THIN FILM FREEZING | OSWALD, KIRSTIN U | — |
| 18082963 | COMPOSITIONS COMPRISING VORICONAZOLE INHALATION POWDER AND METHODS OF MANUFACTURE AND USE THEREOF | RAO, SAVITHA M | — |
| 17742945 | ONCE DAILY FORMULATIONS OF TACROLIMUS | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 3763 | 1 |
| 1691 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18120514 | LARGE SCALE SYNTHESIS OF PHARMACEUTICAL AND BIOLOGIC FORMULATIONS USING THIN FILM FREEZING | OSWALD, KIRSTIN U | 3763 | §103§112 | Non-Final OA | — | Pending | Mar 13, 2023 |
| 18082963 | COMPOSITIONS COMPRISING VORICONAZOLE INHALATION POWDER AND METHODS OF MANUFACTURE AND USE THEREOF | RAO, SAVITHA M | 1691 | §102§103§112 | Final Rejection | — | Pending | Dec 16, 2022 |
| 17742945 | ONCE DAILY FORMULATIONS OF TACROLIMUS | HAGHIGHATIAN, MINA | 1616 | §103 | Non-Final OA | — | Pending | May 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCanvas Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Kirstin U Oswald has the most, with 1 of Canvas Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
